Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

References for PMC Articles for PubMed (Select 23470466)

1.

Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.

Okuno K, Sugiura F, Hida JI, Tokoro T, Ishimaru E, Sukegawa Y, Ueda K.

Exp Ther Med. 2011 Jan;2(1):73-79. Epub 2010 Dec 2.

2.

Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.

Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, Takeda K, Yoshida K, Tsunoda T, Nakamura Y, Mori M, Doki Y.

Int J Oncol. 2012 Oct;41(4):1297-304. doi: 10.3892/ijo.2012.1573. Epub 2012 Jul 25.

PMID:
22842485
3.

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H.

Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29.

PMID:
22842478
4.

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.

Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y.

J Transl Med. 2012 Jul 9;10:141. doi: 10.1186/1479-5876-10-141.

5.

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.

Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H.

Cancer Sci. 2010 Feb;101(2):433-9. doi: 10.1111/j.1349-7006.2009.01416.x. Epub 2009 Oct 27.

PMID:
19930156
6.

Renal cell carcinoma.

Rini BI, Rathmell WK, Godley P.

Curr Opin Oncol. 2008 May;20(3):300-6. doi: 10.1097/CCO.0b013e3282f9782b. Review.

PMID:
18391630
7.

An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.

Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ.

Eur J Cancer. 2008 Jan;44(2):216-23. doi: 10.1016/j.ejca.2007.11.003.

PMID:
18164612
8.

Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients.

Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matsuoka K, Kanayama H.

Cancer Sci. 2007 Dec;98(12):1965-8. Epub 2007 Oct 5.

PMID:
17919310
9.

WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.

Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H.

Microbiol Immunol. 2007;51(5):519-30.

PMID:
17579261
10.

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.

Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K, Itoh K.

Clin Cancer Res. 2006 Mar 15;12(6):1768-75.

11.

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R.

J Cancer Res Clin Oncol. 2006 Mar;132(3):137-49. Epub 2005 Nov 25. Review.

PMID:
16308709
12.

Colorectal cancer vaccines: what we know and what we don't yet know.

von Mehren M.

Semin Oncol. 2005 Feb;32(1):76-84. Review.

PMID:
15726509
13.

Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.

Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW, Schmidt J.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):498-504.

14.

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.

Cancer Immunol Immunother. 2005 Mar;54(3):254-64. Epub 2004 Sep 14.

PMID:
15372205
15.

Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma.

Shimizu K, Uemura H, Yoshikawa M, Yoshida K, Hirao Y, Iwashima K, Saga S, Yoshikawa K.

Oncol Rep. 2003 Sep-Oct;10(5):1307-11.

PMID:
12883698
17.

Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Khong HT, Restifo NP.

Nat Immunol. 2002 Nov;3(11):999-1005. Review.

18.

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.

Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ.

J Exp Med. 2002 Jun 17;195(12):1575-84. Erratum in: J Exp Med 2002 Aug 19;196(4):557.

19.

A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation.

Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K.

Cancer Immunol Immunother. 2002 Jun;51(4):219-28. Epub 2002 Apr 6.

PMID:
12012109
20.

Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients.

Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K.

Int J Cancer. 2002 May 20;99(3):409-17.

PMID:
11992410
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk